Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography.
Adult
Aged
Brain Neoplasms
/ diagnostic imaging
Female
Glioma
/ diagnostic imaging
Humans
Image Interpretation, Computer-Assisted
/ methods
Machine Learning
Male
Middle Aged
Multiple Sclerosis
/ diagnostic imaging
Positron-Emission Tomography
/ methods
Radiopharmaceuticals
Tyrosine
/ analogs & derivatives
Artificial intelligence
Glioma
Multiple sclerosis
PET
Positron emission tomography
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
09
10
2020
accepted:
13
01
2021
pubmed:
28
1
2021
medline:
17
11
2021
entrez:
27
1
2021
Statut:
ppublish
Résumé
This study aimed to test the diagnostic significance of FET-PET imaging combined with machine learning for the differentiation between multiple sclerosis (MS) and glioma II°-IV°. Our database was screened for patients in whom FET-PET imaging was performed for the diagnostic workup of newly diagnosed lesions evident on MRI and suggestive of glioma. Among those, we identified patients with histologically confirmed glioma II°-IV°, and those who later turned out to have MS. For each group, tumor-to-brain ratio (TBR) derived features of FET were determined. A support vector machine (SVM) based machine learning algorithm was constructed to enhance classification ability, and Receiver Operating Characteristic (ROC) analysis with area under the curve (AUC) metric served to ascertain model performance. A total of 41 patients met selection criteria, including seven patients with MS and 34 patients with glioma. TBR values were significantly higher in the glioma group (TBRmax glioma vs. MS: p = 0.002; TBRmean glioma vs. MS: p = 0.014). In a subgroup analysis, TBR values significantly differentiated between MS and glioblastoma (TBRmax glioblastoma vs. MS: p = 0.0003, TBRmean glioblastoma vs. MS: p = 0.0003) and between MS and oligodendroglioma (ODG) (TBRmax ODG vs. MS: p = 0.003; TBRmean ODG vs. MS: p = 0.01). The ability to differentiate between MS and glioma II°-IV° increased from 0.79 using standard TBR analysis to 0.94 using a SVM based machine learning algorithm. FET-PET imaging may help differentiate MS from glioma II°-IV° and SVM based machine learning approaches can enhance classification performance.
Identifiants
pubmed: 33502678
doi: 10.1007/s11060-021-03701-1
pii: 10.1007/s11060-021-03701-1
doi:
Substances chimiques
Radiopharmaceuticals
0
(18F)fluoroethyltyrosine
1326R5J1IA
Tyrosine
42HK56048U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-332Références
Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ (2014) Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83:1022–1024. https://doi.org/10.1212/wnl.0000000000000768
doi: 10.1212/wnl.0000000000000768
pubmed: 25200713
pmcid: 4162299
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintore M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/s1474-4422(17)30470-2
doi: 10.1016/s1474-4422(17)30470-2
pubmed: 29275977
Hardy TA (2019) Pseudotumoral demyelinating lesions: diagnostic approach and long-term outcome. Curr Opin Neurol 32:467–474. https://doi.org/10.1097/wco.0000000000000683
doi: 10.1097/wco.0000000000000683
pubmed: 30844860
Jakola AS, Skjulsvik AJ, Myrmel KS, Sjavik K, Unsgard G, Torp SH, Aaberg K, Berg T, Dai HY, Johnsen K, Kloster R, Solheim O (2017) Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 28:1942–1948. https://doi.org/10.1093/annonc/mdx230
doi: 10.1093/annonc/mdx230
pubmed: 28475680
pmcid: 5834105
Hayashi T, Kumabe T, Jokura H, Fujihara K, Shiga Y, Watanabe M, Higano S, Shirane R (2003) Inflammatory demyelinating disease mimicking malignant glioma. J Nucl Med 44:565–569
pubmed: 12679401
Kebir S, Gaertner FC, Mueller M, Nelles M, Simon M, Schafer N, Stuplich M, Schaub C, Niessen M, Mack F, Bundschuh R, Greschus S, Essler M, Glas M, Herrlinger U (2016) (18)F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: a case report. Oncol Lett 11:2195–2198. https://doi.org/10.3892/ol.2016.4189
doi: 10.3892/ol.2016.4189
pubmed: 26998148
pmcid: 4774557
Pakos EE, Tsekeris PG, Chatzidimou K, Goussia AC, Markoula S, Argyropoulou MI, Pitouli EG, Konitsiotis S (2005) Astrocytoma-like multiple sclerosis. Clin Neurol Neurosurg 107:152–157. https://doi.org/10.1016/j.clineuro.2004.06.003
doi: 10.1016/j.clineuro.2004.06.003
pubmed: 15708234
Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N’Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S, Francophone S (2018) Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. J Neurol 265:2251–2259. https://doi.org/10.1007/s00415-018-8984-7
doi: 10.1007/s00415-018-8984-7
pubmed: 30054790
Kim DS, Na DG, Kim KH, Kim JH, Kim E, Yun BL, Chang KH (2009) Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 251:467–475. https://doi.org/10.1148/radiol.2512072071
doi: 10.1148/radiol.2512072071
pubmed: 19261924
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, la Fougere C, Langen KJ, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn JC, Weller M (2019) Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18) F] FDG: version 1.0. Eur J Nucl Med Mol Imaging 46:540–557. https://doi.org/10.1007/s00259-018-4207-9
doi: 10.1007/s00259-018-4207-9
pubmed: 30519867
Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Muller HW, Coenen HH, Langen KJ (2003) Whole-body distribution and dosimetry of O-(2-[18F] fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging 30:519–524. https://doi.org/10.1007/s00259-003-1118-0
doi: 10.1007/s00259-003-1118-0
pubmed: 12589478
Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Fluss MO, Hamacher K, Coenen HH, Langen KJ (2006) 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 47:256–261
pubmed: 16455631
Rau FC, Weber WA, Wester HJ, Herz M, Becker I, Kruger A, Schwaiger M, Senekowitsch-Schmidtke R (2002) O-(2-[(18) F] Fluoroethyl) - L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 29:1039–1046. https://doi.org/10.1007/s00259-002-0821-6
doi: 10.1007/s00259-002-0821-6
pubmed: 12173018
Chang CH, Wang HE, Wu SY, Fan KH, Tsai TH, Lee TW, Chang SR, Liu RS, Chen CF, Chen CH, Fu YK (2006) Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice. Anticancer Res 26:917–925
pubmed: 16619487
Barbagallo M, Albatly AA, Schreiner S, Hayward-Konnecke HK, Buck A, Kollias SS, Huellner MW (2018) Value of 18F-FET PET in patients with suspected tumefactive demyelinating disease-preliminary experience from a retrospective analysis. Clin Nucl Med 43:e385–e391. https://doi.org/10.1097/rlu.0000000000002244
doi: 10.1097/rlu.0000000000002244
pubmed: 30153143
Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W, Rommel F, Hamacher K, Langen KJ (2006) 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 47:776–782
pubmed: 16644747
Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nussbaumer K, Topakian R, Aigner RM (2010) Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 37:1521–1528. https://doi.org/10.1007/s00259-010-1457-6
doi: 10.1007/s00259-010-1457-6
pubmed: 20396883
Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, Sabel M, Steiger HJ, Reifenberger G, Beez T, Coenen HH, Floeth FW, Langen KJ (2013) Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 54:229–235. https://doi.org/10.2967/jnumed.112.109603
doi: 10.2967/jnumed.112.109603
pubmed: 23232275
Hashimoto S, Inaji M, Nariai T, Kobayashi D, Sanjo N, Yokota T, Ishii K, Taketoshi M (2019) Usefulness of [(11) C] methionine PET in the differentiation of tumefactive multiple sclerosis from high grade astrocytoma. Neurol Med Chir 59:176–183. https://doi.org/10.2176/nmc.oa.2018-0287
doi: 10.2176/nmc.oa.2018-0287
Topol EJ (2019) High-performance medicine: the convergence of human and artificial intelligence. Nat Med 25:44–56. https://doi.org/10.1038/s41591-018-0300-7
doi: 10.1038/s41591-018-0300-7
pubmed: 30617339
Kebir S, Lazaridis L, Weber M, Deuschl C, Stoppek AK, Schmidt T, Monninghoff C, Blau T, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Stuschke M, Antoch G, Sure U, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Herrmann K, Glas M (2019) Comparison of L-Methyl-11C-methionine PET with magnetic resonance spectroscopy in detecting newly diagnosed glioma. Clin Nucl Med 44:e375–e381. https://doi.org/10.1097/rlu.0000000000002577
doi: 10.1097/rlu.0000000000002577
pubmed: 30985412
Kebir S, Weber M, Lazaridis L, Deuschl C, Schmidt T, Monninghoff C, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Sure U, Stuschke M, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Rischpler C, Glas M (2019) Hybrid 11C-MET PET/MRI combined with “machine learning” in glioma diagnosis according to the revised glioma WHO classification 2016. Clin Nucl Med 44:214–220. https://doi.org/10.1097/rlu.0000000000002398
doi: 10.1097/rlu.0000000000002398
pubmed: 30516675
Vallieres M, Kay-Rivest E, Perrin LJ, Liem X, Furstoss C, Aerts H, Khaouam N, Nguyen-Tan PF, Wang CS, Sultanem K, Seuntjens J, El Naqa I (2017) Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci Rep 7:10117. https://doi.org/10.1038/s41598-017-10371-5
doi: 10.1038/s41598-017-10371-5
pubmed: 28860628
pmcid: 5579274
Wiyaporn K, Tocharoenchai C, Pusuwan P, Ekjeen T, Leaungwutiwong S, Thanyarak S (2010) Factors affecting standardized uptake value (SUV) of positron emission tomography (PET) imaging with l8F-FDG. J Med Assoc Thai 93:108–114
pubmed: 20196419
Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Fürst S, Martinez-Möller A, Nekolla SG, Ziegler S, Ganter C, Rummeny EJ, Schwaiger M (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53:845–855. https://doi.org/10.2967/jnumed.111.098608
doi: 10.2967/jnumed.111.098608
pubmed: 22534830
Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L (2010) Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 51:1198–1205. https://doi.org/10.2967/jnumed.110.074773
doi: 10.2967/jnumed.110.074773
Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Lohr M, Herrmann K (2014) Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med 55:1611–1616. https://doi.org/10.2967/jnumed.114.140608
doi: 10.2967/jnumed.114.140608
pubmed: 25125481
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
Huang S, Cai N, Pacheco PP, Narrandes S, Wang Y, Xu W (2018) Applications of support vector machine (SVM) learning in cancer genomics. Cancer Genomics Proteomics 15:41–51. https://doi.org/10.21873/cgp.20063
doi: 10.21873/cgp.20063
pubmed: 29275361
Jordan MI, Mitchell TM (2015) Machine learning: trends, perspectives, and prospects. Science 349:255–260. https://doi.org/10.1126/science.aaa8415
doi: 10.1126/science.aaa8415
pubmed: 26185243
Smits A, Baumert BG (2011) The clinical value of PET with amino acid tracers for gliomas WHO grade II. Int J Mol Imaging 2011:372509. https://doi.org/10.1155/2011/372509
doi: 10.1155/2011/372509
pubmed: 21603237
pmcid: 3094834
Glotsos D, Spyridonos P, Cavouras D, Ravazoula P, Dadioti PA, Nikiforidis G (2005) An image-analysis system based on support vector machines for automatic grade diagnosis of brain-tumour astrocytomas in clinical routine. Med Inform Internet Med 30:179–193. https://doi.org/10.1080/14639230500077444
doi: 10.1080/14639230500077444
pubmed: 16403707
Filss CP, Albert NL, Böning G, Kops ER, Suchorska B, Stoffels G, Galldiks N, Shah NJ, Mottaghy FM, Bartenstein P, Tonn JC, Langen KJ (2017) O-(2-[(18) F] fluoroethyl)-L-tyrosine PET in gliomas: influence of data processing in different centres. EJNMMI Res 7:64. https://doi.org/10.1186/s13550-017-0316-x
doi: 10.1186/s13550-017-0316-x
pubmed: 28815478
pmcid: 5559408
Cunliffe CH, Fischer I, Monoky D, Law M, Revercomb C, Elrich S, Kopp MJ, Zagzag D (2009) Intracranial lesions mimicking neoplasms. Arch Pathol Lab Med 133:101–123. https://doi.org/10.1043/1543-2165-133.1.101
doi: 10.1043/1543-2165-133.1.101
pubmed: 19123722